François Thomas

GamaMabs Pharma SA specializes in developing monoclonal antibodies. It offers research and development solutions for biopharmaceutical industry. The company was founded by Jean-Francois Prost and Stephane Degove in June 2013 and is headquartered in Toulouse, France.

Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France.

GamaMabs Pharma SA specializes in developing monoclonal antibodies. It offers research and development solutions for biopharmaceutical industry. The company was founded by Jean-Francois Prost and Stephane Degove in June 2013 and is headquartered in Toulouse, France.

Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France.

Axilum Robotics SAS develops and commercializes robotic solutions designed to assist medical professionals in the implementation of technical gestures. Its first project is a robot to assist psychiatrists and neurologists for Transcranial Magnetic Stimulation (TMS). The firm's project TMS is a painless, non invasive medical technique that applies high intensity magnetic impulses to cortex areas by placing a coil on the surface of the head. The company was founded by Bernard Bayle, Michel Berg, Michel de Mathelin, Romuald Ginhoux, Benjamin Maurin and Pierre Renaud in April 2011 and is headquartered in Strasbourg, France.

Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France.

Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States.

Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States.

Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States.

Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States.

Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States.

Sofimac Régions SAS is a Private Equity/Venture Capital firm, a subsidiary of Sofimac Investment Managers SAS founded in 1978. Sofimac Régions is headquartered in Clermont-Ferrand.

Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States.

Biomodex SAS develops 3D printed surgical simulators for medical education and patient-specific preoperative planning. It offers simulators for surgical procedures such as bone drilling, soft tissue suturing, medical device implantation, and sizing. The company was founded by Thomas Marchand and Sidarth Radjou on January 22, 2015 and is headquartered in Paris, France.

Axilum Robotics SAS develops and commercializes robotic solutions designed to assist medical professionals in the implementation of technical gestures. Its first project is a robot to assist psychiatrists and neurologists for Transcranial Magnetic Stimulation (TMS). The firm's project TMS is a painless, non invasive medical technique that applies high intensity magnetic impulses to cortex areas by placing a coil on the surface of the head. The company was founded by Bernard Bayle, Michel Berg, Michel de Mathelin, Romuald Ginhoux, Benjamin Maurin and Pierre Renaud in April 2011 and is headquartered in Strasbourg, France.

Axilum Robotics SAS develops and commercializes robotic solutions designed to assist medical professionals in the implementation of technical gestures. Its first project is a robot to assist psychiatrists and neurologists for Transcranial Magnetic Stimulation (TMS). The firm's project TMS is a painless, non invasive medical technique that applies high intensity magnetic impulses to cortex areas by placing a coil on the surface of the head. The company was founded by Bernard Bayle, Michel Berg, Michel de Mathelin, Romuald Ginhoux, Benjamin Maurin and Pierre Renaud in April 2011 and is headquartered in Strasbourg, France.

GamaMabs Pharma SA specializes in developing monoclonal antibodies. It offers research and development solutions for biopharmaceutical industry. The company was founded by Jean-Francois Prost and Stephane Degove in June 2013 and is headquartered in Toulouse, France.

Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France.

Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States.

Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States.

Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States.

Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States.

Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States.

Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States.

Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States.

Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States.

Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France.

Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States.

Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States.

Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States.

Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States.

Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France.

Cardiawave SA develops non-invasive medical device to treat a heart condition called aortic stenosis. The company was founded by Emmanuel Messas, Benjamin Bertrand, Mickaël Tanter, Mathieu Pernot and Mathias Fink on October 21, 2014 and is headquartered in Paris, France.

Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States.

Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States.

Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States.

Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States.

Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France.

Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France.

Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France.

Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France.

Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States.

Cardiawave SA develops non-invasive medical device to treat a heart condition called aortic stenosis. The company was founded by Emmanuel Messas, Benjamin Bertrand, Mickaël Tanter, Mathieu Pernot and Mathias Fink on October 21, 2014 and is headquartered in Paris, France.

Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States.

Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France.

Axilum Robotics SAS develops and commercializes robotic solutions designed to assist medical professionals in the implementation of technical gestures. Its first project is a robot to assist psychiatrists and neurologists for Transcranial Magnetic Stimulation (TMS). The firm's project TMS is a painless, non invasive medical technique that applies high intensity magnetic impulses to cortex areas by placing a coil on the surface of the head. The company was founded by Bernard Bayle, Michel Berg, Michel de Mathelin, Romuald Ginhoux, Benjamin Maurin and Pierre Renaud in April 2011 and is headquartered in Strasbourg, France.

Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France.

Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States.

Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France.

Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States.